DIANTHUS THERAPEUTICS INC. - COMMON STOCK

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

08 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

07 ноя 2024 16:01:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

04 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

15 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

04 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

08 авг 2024 16:01:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

28 июн 2024 11:30:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

12 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

30 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

09 май 2024 16:01:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

08 май 2024 16:30:54 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

11 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 апр 2024 16:30:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

21 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

26 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire